Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | TSPO | P30536 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172473 | 0.89 | GRM5 (0.59) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL4631050 | 0.88 | GRM5 (0.74) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2174588 | 0.88 | GRM5 (0.63) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2175568 | 0.88 | GRM5 (0.63) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL29378035 | 0.86 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2172336 | 0.86 | GRM5 (0.78) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL981728 | 0.86 | GRM5 (0.62) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2177266 | 0.84 | GRM5 (0.58) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2173896 | 0.82 | GRM5 (0.61) | GRM5KCNH2ADRB3TSPOTMEM97 | |
| SCHEMBL2175507 | 0.81 | GRM5 (0.64) | GRM5KCNH2ADRB3TSPOTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481548-B2 | 2-[4-(2-chloro-pyridin-4-ylethynyl)-2-methyl-imidazol-1-yl]-4-trifluoromethyl-pyrimidine; metabotropic glutamate (mGluR5) receptor antagonist; analgesic, neurodegenerative diseases; psychosis, epilepsy, schizophrenia, Alzheimer' disease, cognititve disorders, memory deficits, chronic and acute pain | HOFFMAN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-7973165-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7531529-B2 | Imidazole derivatives | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080119489-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2008-05-22 | — | — | US | disclosed |
| US-20080103306-A1 | IMIDAZOLE DERIVATIVES | BUETTELMANN BERND | 2008-05-01 | — | — | US | disclosed |
| US-7332510-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1636206-B1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2007-10-31 | — | — | EP | disclosed |
| EP-1636206-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| US-20050143375-A1 | Imidazole derivatives | ROCHE PALO ALTO LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004108701-A1 | IMIDAZOLE DERIVATIVES AS GLUTMATE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248888-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119489-A1 | IMIDAZOLE DERIVATIVES | GRIK5, GRM5, GRIN2B | GRM5 2/4885KCNH2 140/4885ADRB3 806/4885 |
| US-20080103306-A1 | IMIDAZOLE DERIVATIVES | GRIK5, GRM5, GRIN2B | GRM5 2/4885KCNH2 132/4885ADRB3 1082/4885 |
| US-20040248888-A1 | Imidazole derivatives | GRIK5, GRM5, GRIN2B | GRM5 2/4885KCNH2 115/4885ADRB3 991/4885 |
| US-20050143375-A1 | Imidazole derivatives | GRM5, GRIK5, GRM2 | GRM5 1/4885KCNH2 1004/4885ADRB3 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.